COVID-19 Vaccine Efficacy Higher With Three-Month Interval Between Doses
For ChAdOx1 nCoV-19 Oxford vaccine, three-month interval results in higher efficacy than six-week interval
All British Adults Should Have First COVID-19 Shot by July 31: Government
Announcement made as government prepares a 'cautious' reopening plan
CDC Report Shows No Evidence of Unexpected Adverse Events With COVID-19 Vaccines
Findings from the first month show no unexpected adverse events, with 6,994 adverse events and >90 percent classified as nonserious
SARS-CoV-2, COVID-19 Rates Decreased After One Vaccine Dose
Study among health care workers shows reductions in SARS-CoV-2 infection rates one to 14, 15 to 28 days after first dose of the BNT162b2 COVID-19 vaccine
Physician’s Briefing Weekly Coronavirus Roundup
U.S. to Provide $4 Billion for International COVID-19 Vaccine Program
U.N. Secretary-General Antonio Guterres says that 130 countries have not received a single dose of the vaccine
Pfizer to Begin Clinical Trial of COVID-19 Vaccine in Pregnant Women
Pfizer also planning to start trials of the vaccine in younger children, teens, people with weakened immune systems
T2DM in Middle Age Ups Mortality Risk in COVID-19 Infection
Excess COVID-19 death risk from type 2 diabetes decreases with increasing age
Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
Progression-free, overall survival significantly longer with combo versus sunitinib for advanced renal cell carcinoma
Relugolix Combo Therapy Beneficial for Fibroid-Related Menorrhagia
Significantly more women had reduced menstrual bleeding with once-daily relugolix combination therapy versus placebo
